CYP2D6 rs7770370: Pharmacogenomics and Drug Metabolism
The rs7770370 variant is a single-nucleotide polymorphism located in an intronic region of the cytochrome P450 2D6 (CYP2D6) gene cluster on chromosome 22. It has been examined in clinical research cohorts for its association with altered metabolic activation rates of prodrugs such as tamoxifen and codeine. However, current pharmacogenomic evidence evaluating rs7770370 as an independent clinical predictor remains limited compared to standard CYP2D6 star-allele haplotypes.
What each genotype means
| Genotype | What the research suggests | Reading |
|---|---|---|
| CC | Homozygous for the reference C allele. In pharmacogenomic association cohorts, this genotype is generally considered the baseline profile, reflecting standard activity unless co-inherited with other functional star-allele variations. | Informational |
| CT | Heterozygous carrying one copy of the alternate T allele. This genotype has been examined in association studies for intermediate metabolic conversion rates of certain CYP2D6 substrates, although clinical implications depend on broader haplotype context. | Informational |
| TT | Homozygous for the alternate T allele. While clinical evidence remains limited, some cohorts associate this genotype with altered metabolic rates of CYP2D6 prodrugs due to linkage with specific reduced-function haplotypes. | Higher attention |
Genomic Location and Variant Characteristics
The single-nucleotide polymorphism rs7770370 is situated on chromosome 22q13.2 within the CYP2D gene cluster, which contains the active CYP2D6 gene alongside highly homologous pseudogenes CYP2D7 and CYP2D8. This specific variant resides within a non-coding intronic region of CYP2D6. Because it does not alter an amino acid sequence directly, rs7770370 is primarily evaluated as a tag SNP or linkage marker that may co-segregate with functional haplotype alleles. The genomic architecture of the CYP2D6 locus is notoriously complex, characterized by dense sequence homology, single-nucleotide variations, and frequent structural rearrangements such as gene duplications and deletions. Consequently, isolated intronic variants like rs7770370 are typically contextualized by their proximity to established functional star alleles defined by international pharmacogenomic consortia.
The Biological Function of CYP2D6
The CYP2D6 gene encodes cytochrome P450 family 2 subfamily D member 6, a membrane-bound hepatic enzyme responsible for the phase I oxidative metabolism of roughly 20 to 25 percent of all clinically prescribed medications. Despite constituting a modest fraction of total hepatic cytochrome P450 protein content, CYP2D6 plays a pivotal role in bioactivating prodrugs into active therapeutic compounds and clearing active molecules into excretable forms. Key substrates metabolized through CYP2D6 pathways include opioids such as codeine and tramadol, selective estrogen receptor modulators like tamoxifen, tricyclic antidepressants, selective serotonin reuptake inhibitors, beta-blockers, and antiarrhythmics. Individual enzyme capacity spans a wide spectrum, historically categorized into poor, intermediate, normal, and ultrarapid metabolizer phenotypes based on inherited genetic variation.
Research Associations and Evidence Strength
In observational pharmacogenomic studies, rs7770370 has been investigated for potential correlations with systemic drug exposure and conversion rates, particularly for tamoxifen bioactivation into potent anti-estrogen metabolites like endoxifen, and the O-demethylation of codeine into morphine. However, the overall strength of evidence directly tying rs7770370 to altered drug efficacy or adverse outcomes is classified as limited. In modern clinical pharmacogenetics, major consortium guidelines—including those from the Clinical Pharmacogenetics Implementation Consortium (CPIC) and PharmGKB—rely on comprehensive star-allele definitions (such as CYP2D6*4, *10, or *41) and copy number variations rather than standalone intronic markers. Because rs7770370 often co-occurs with other variants on specific ancestral haplotype backgrounds, isolating its individual biological effect remains challenging.
Navigating Pharmacogenomic Results Responsibly
Identifying an individual genotype at rs7770370 provides educational insight into genomic diversity across the CYP2D locus, but it cannot be used on its own to determine clinical drug response or replace comprehensive clinical phenotyping. Commercial sequencing platforms that report individual SNPs frequently omit critical structural variations, such as full gene deletions (*5) or multi-copy duplications, which heavily shape real-world enzyme activity. Patients should never initiate, discontinue, or alter the dosage of any prescribed medication based on direct-to-consumer genetic readouts. Decisions regarding drug choice and dose adjustments require consultation with a licensed physician or clinical pharmacogenomics specialist, who can interpret genetic findings within the context of validated clinical guidelines, concomitant medications, liver function, and overall clinical history.
How common is this variant?
The minor allele (T) exhibits moderate frequency worldwide, observed at approximately 0.35 in European populations and roughly 0.42 in East Asian cohorts, with variations across global population databases.
Frequently asked questions
What is the CYP2D6 rs7770370 variant?
The rs7770370 variant is an intronic single-nucleotide polymorphism located within the CYP2D6 gene cluster on chromosome 22. It is studied in pharmacogenomics to understand individual differences in the processing of specific medications.
Does rs7770370 determine how I metabolize tamoxifen or codeine?
Not independently. While rs7770370 has been associated with drug conversion rates in research cohorts, established clinical prescribing guidelines rely on multi-variant star-allele haplotypes and copy number variations rather than this single marker.
Should I change my medication dose based on my rs7770370 genotype?
No, you should never modify your prescription dosages or stop taking any medication based on a single SNP result. Any questions about drug therapy, efficacy, or side effects should be discussed directly with your healthcare provider or a clinical pharmacist.
How common is the rs7770370 variant across different ancestries?
The minor allele is relatively common across major global populations, with an estimated frequency of approximately 35% in individuals of European ancestry and roughly 42% in East Asian populations.
Sources & further reading
Educational information only, last refreshed 9/6/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs7770370?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29